Representative Vern Buchanan's (R-FL) Chronic Disease Flexible Coverage Act has passed the House of Representatives and will now go to the Senate.
The bipartisan bill, which Rep. Buchanan introduced with Representative Jimmy Panetta (D-CA) in early February, allows employers that offer high-deductible health plans (HDHP) to employees an option to include pre-deductible coverage of healthcare services treating common chronic diseases, a policy first implemented in President Donald Trump's first term in 2019.
Healthcare services listed in Rep. Buchanan's legislation include beta blockers for congestive heart failure, blood pressure monitors, glucometers for diabetes, asthma inhalers, and cholesterol drugs for heart disease patients.
In his press release, the Florida Congressman said, "With six in ten Americans living with at least one chronic disease, it is clear that we must expand options for people to manage their chronic health conditions. The Chronic Disease Flexible Coverage Act offers employees more flexibility to manage their chronic diseases, improving patient health while reducing high out-of-pocket costs. I'm proud that this legislation passed the House with unanimous bipartisan support, and I look forward to getting this bill signed into law."
With Republicans controlling the Senate and White House, Buchanan's wish could soon be granted.
The Chronic Disease Flexible Coverage Act is the Florida Congressman's second major healthcare bill introduced in the new Congress, with the first being the Maximizing Israel-U.S. Research Advancement and Collaborative Leadership in Emerging (MIRACLE) Medical Technology Act.
The MIRACLE Act strengthens medical research and development collaboration between the United States and Israel, including creating a U.S.-Israel Health Care Collaboration Center.
More recently, Buchanan introduced two more bipartisan healthcare bills. The Permanent Telehealth from Home Act permanently removes the originating site and geographic limitations for telehealth services, meaning they can be accessed anywhere.
The other, the Lung Cancer Screening and Prevention Act, expedites approval processes for new lung cancer screening tests through the Food and Drug Administration (FDA).
